 |
인쇄하기
취소
|
Price re-assessment of Crestor is still under negotiation
Now all eyes are on the Health Insurance Review & Assessment Service’s committee decision on the price readjustment of Crestor, a lipid-lowering agent.
According to the HIRA, the re-assessment is likely to take time since the committee’s members failed to reach an agreement over the methodology of comparative doses between simvastatin 40mg and Crestor 5 mg and 10 mg.
Civic groups advocati...
According to the HIRA, the re-assessment is likely to take time since the committee’s members failed to reach an agreement over the methodology of comparative doses between simvastatin 40mg and Crestor 5 mg and 10 mg.
Civic groups advocati...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.